AU2010210540B2 - Methods and compositions for diagnosis and prognosis of renal injury and failure - Google Patents
Methods and compositions for diagnosis and prognosis of renal injury and failure Download PDFInfo
- Publication number
- AU2010210540B2 AU2010210540B2 AU2010210540A AU2010210540A AU2010210540B2 AU 2010210540 B2 AU2010210540 B2 AU 2010210540B2 AU 2010210540 A AU2010210540 A AU 2010210540A AU 2010210540 A AU2010210540 A AU 2010210540A AU 2010210540 B2 AU2010210540 B2 AU 2010210540B2
- Authority
- AU
- Australia
- Prior art keywords
- subject
- renal
- threshold
- likelihood
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 200
- 206010061481 Renal injury Diseases 0.000 title claims abstract description 81
- 238000003745 diagnosis Methods 0.000 title claims abstract description 60
- 208000001647 Renal Insufficiency Diseases 0.000 title claims description 26
- 201000006370 kidney failure Diseases 0.000 title claims description 26
- 239000000203 mixture Substances 0.000 title abstract description 8
- 238000004393 prognosis Methods 0.000 title abstract description 8
- 238000003556 assay Methods 0.000 claims abstract description 182
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 294
- 230000003907 kidney function Effects 0.000 claims description 221
- 210000002966 serum Anatomy 0.000 claims description 158
- 229940109239 creatinine Drugs 0.000 claims description 147
- 201000011040 acute kidney failure Diseases 0.000 claims description 129
- 230000006378 damage Effects 0.000 claims description 123
- 208000014674 injury Diseases 0.000 claims description 123
- 208000027418 Wounds and injury Diseases 0.000 claims description 120
- 208000033626 Renal failure acute Diseases 0.000 claims description 90
- 102000008791 Lysozyme C Human genes 0.000 claims description 77
- 108050000633 Lysozyme C Proteins 0.000 claims description 77
- 230000002829 reductive effect Effects 0.000 claims description 60
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 48
- 230000001154 acute effect Effects 0.000 claims description 42
- 230000003247 decreasing effect Effects 0.000 claims description 42
- 201000010099 disease Diseases 0.000 claims description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 42
- 210000001124 body fluid Anatomy 0.000 claims description 40
- 239000010839 body fluid Substances 0.000 claims description 39
- 230000006872 improvement Effects 0.000 claims description 36
- 230000008859 change Effects 0.000 claims description 35
- 238000000502 dialysis Methods 0.000 claims description 35
- 230000024924 glomerular filtration Effects 0.000 claims description 32
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 30
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims description 30
- 238000002054 transplantation Methods 0.000 claims description 30
- 239000002872 contrast media Substances 0.000 claims description 24
- 206010019280 Heart failures Diseases 0.000 claims description 23
- 208000012998 acute renal failure Diseases 0.000 claims description 20
- 208000020832 chronic kidney disease Diseases 0.000 claims description 19
- 206010040047 Sepsis Diseases 0.000 claims description 17
- 229930182912 cyclosporin Natural products 0.000 claims description 17
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 17
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 17
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 17
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 16
- 108010036941 Cyclosporins Proteins 0.000 claims description 16
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 16
- 108010062374 Myoglobin Proteins 0.000 claims description 16
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 16
- 229940126575 aminoglycoside Drugs 0.000 claims description 16
- 206010012601 diabetes mellitus Diseases 0.000 claims description 16
- 229940093476 ethylene glycol Drugs 0.000 claims description 16
- 229960000485 methotrexate Drugs 0.000 claims description 16
- 229960001967 tacrolimus Drugs 0.000 claims description 16
- 102000001554 Hemoglobins Human genes 0.000 claims description 15
- 108010054147 Hemoglobins Proteins 0.000 claims description 15
- 206010020772 Hypertension Diseases 0.000 claims description 15
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims description 15
- 208000029078 coronary artery disease Diseases 0.000 claims description 15
- 229960005102 foscarnet Drugs 0.000 claims description 15
- 229910001385 heavy metal Inorganic materials 0.000 claims description 15
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 15
- 229960001101 ifosfamide Drugs 0.000 claims description 15
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 15
- 229960001052 streptozocin Drugs 0.000 claims description 15
- 208000002296 eclampsia Diseases 0.000 claims description 14
- 201000011461 pre-eclampsia Diseases 0.000 claims description 14
- 201000001474 proteinuria Diseases 0.000 claims description 14
- 201000000523 end stage renal failure Diseases 0.000 claims description 11
- 208000028208 end stage renal disease Diseases 0.000 claims description 10
- 238000011156 evaluation Methods 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- 238000007675 cardiac surgery Methods 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 230000007882 cirrhosis Effects 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 210000004351 coronary vessel Anatomy 0.000 claims description 4
- 238000007631 vascular surgery Methods 0.000 claims description 4
- 102000036675 Myoglobin Human genes 0.000 claims 1
- 230000009692 acute damage Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 abstract description 58
- 238000011269 treatment regimen Methods 0.000 abstract description 9
- 102000030914 Fatty Acid-Binding Human genes 0.000 abstract description 8
- 102000004042 Fibroblast Growth Factor-23 Human genes 0.000 abstract description 8
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 abstract description 8
- 102000013462 Interleukin-12 Human genes 0.000 abstract description 8
- 108010065805 Interleukin-12 Proteins 0.000 abstract description 8
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 abstract description 8
- 102000052586 bactericidal permeability increasing protein Human genes 0.000 abstract description 8
- 108010032816 bactericidal permeability increasing protein Proteins 0.000 abstract description 8
- 108091022862 fatty acid binding Proteins 0.000 abstract description 8
- 229940117681 interleukin-12 Drugs 0.000 abstract description 8
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 abstract 1
- 239000000104 diagnostic biomarker Substances 0.000 abstract 1
- 239000000092 prognostic biomarker Substances 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 description 189
- 210000002381 plasma Anatomy 0.000 description 135
- 239000003550 marker Substances 0.000 description 92
- 239000000523 sample Substances 0.000 description 74
- 230000035945 sensitivity Effects 0.000 description 70
- 102000008857 Ferritin Human genes 0.000 description 65
- 108050000784 Ferritin Proteins 0.000 description 65
- 201000003068 rheumatic fever Diseases 0.000 description 62
- 238000008416 Ferritin Methods 0.000 description 61
- 230000002596 correlated effect Effects 0.000 description 61
- 238000005259 measurement Methods 0.000 description 50
- 208000037806 kidney injury Diseases 0.000 description 48
- 238000013517 stratification Methods 0.000 description 48
- 238000004458 analytical method Methods 0.000 description 45
- 238000003018 immunoassay Methods 0.000 description 40
- 108090000765 processed proteins & peptides Proteins 0.000 description 39
- 239000000090 biomarker Substances 0.000 description 38
- 229920001184 polypeptide Polymers 0.000 description 38
- 102000004196 processed proteins & peptides Human genes 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 36
- 239000008280 blood Substances 0.000 description 36
- 238000012360 testing method Methods 0.000 description 34
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 31
- 229910052708 sodium Inorganic materials 0.000 description 31
- 239000011734 sodium Substances 0.000 description 31
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 22
- 230000000875 corresponding effect Effects 0.000 description 22
- 210000003734 kidney Anatomy 0.000 description 21
- 108010051335 Lipocalin-2 Proteins 0.000 description 20
- 102000013519 Lipocalin-2 Human genes 0.000 description 20
- 239000012491 analyte Substances 0.000 description 19
- 238000001356 surgical procedure Methods 0.000 description 19
- 230000002123 temporal effect Effects 0.000 description 19
- 239000007790 solid phase Substances 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- 102100030856 Myoglobin Human genes 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 239000003053 toxin Substances 0.000 description 15
- 231100000765 toxin Toxicity 0.000 description 15
- 108700012359 toxins Proteins 0.000 description 15
- 230000029142 excretion Effects 0.000 description 14
- 208000017169 kidney disease Diseases 0.000 description 13
- 230000009467 reduction Effects 0.000 description 13
- 102000012192 Cystatin C Human genes 0.000 description 12
- 108010061642 Cystatin C Proteins 0.000 description 12
- 238000012959 renal replacement therapy Methods 0.000 description 12
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 11
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 10
- 102100036836 Natriuretic peptides B Human genes 0.000 description 10
- 101710187802 Natriuretic peptides B Proteins 0.000 description 10
- 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 description 10
- 208000023146 Pre-existing disease Diseases 0.000 description 10
- 230000036772 blood pressure Effects 0.000 description 10
- 230000005484 gravity Effects 0.000 description 10
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 10
- 230000002250 progressing effect Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000029058 respiratory gaseous exchange Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 102000013382 Gelatinases Human genes 0.000 description 9
- 108010026132 Gelatinases Proteins 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 102000000546 Apoferritins Human genes 0.000 description 8
- 108010002084 Apoferritins Proteins 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 8
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 8
- 208000015698 cervical squamous intraepithelial neoplasia Diseases 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 102100029599 Advanced glycosylation end product-specific receptor Human genes 0.000 description 7
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 7
- 229940039231 contrast media Drugs 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000010024 tubular injury Effects 0.000 description 7
- 208000037978 tubular injury Diseases 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000007717 exclusion Effects 0.000 description 6
- 201000006334 interstitial nephritis Diseases 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- -1 100% Chemical compound 0.000 description 5
- 208000017667 Chronic Disease Diseases 0.000 description 5
- 239000004971 Cross linker Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 4
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 4
- 230000001434 glomerular Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- WFLQAMUOBIONDG-UHFFFAOYSA-N phenoxyarsonic acid Chemical compound O[As](O)(=O)OC1=CC=CC=C1 WFLQAMUOBIONDG-UHFFFAOYSA-N 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000004082 amperometric method Methods 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 238000003066 decision tree Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 238000002848 electrochemical method Methods 0.000 description 3
- 238000000572 ellipsometry Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940089988 hep-lock Drugs 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000005305 interferometry Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000002923 metal particle Substances 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 2
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 2
- 101710145634 Antigen 1 Proteins 0.000 description 2
- 201000003126 Anuria Diseases 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 2
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 2
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 2
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100037738 Fatty acid-binding protein, heart Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 102100025392 Isovaleryl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 2
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 2
- 206010030302 Oliguria Diseases 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 102000014456 Trefoil Factor-3 Human genes 0.000 description 2
- 108010078184 Trefoil Factor-3 Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 102000018614 Uromodulin Human genes 0.000 description 2
- 108010027007 Uromodulin Proteins 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940124572 antihypotensive agent Drugs 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 238000013130 cardiovascular surgery Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108091007169 meprins Proteins 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 108010055851 Acetylglucosaminidase Proteins 0.000 description 1
- 206010068625 Acquired phimosis Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100022463 Alpha-1-acid glycoprotein 1 Human genes 0.000 description 1
- 101710186701 Alpha-1-acid glycoprotein 1 Proteins 0.000 description 1
- 102000003966 Alpha-1-microglobulin Human genes 0.000 description 1
- 101800001761 Alpha-1-microglobulin Proteins 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 101800001718 Amyloid-beta protein Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005060 Bladder obstruction Diseases 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 description 1
- 102100023703 C-C motif chemokine 15 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 108010049990 CD13 Antigens Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 208000006017 Cardiac Tamponade Diseases 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000052052 Casein Kinase II Human genes 0.000 description 1
- 108010010919 Casein Kinase II Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 102000003780 Clusterin Human genes 0.000 description 1
- 108090000197 Clusterin Proteins 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000005889 Cysteine-Rich Protein 61 Human genes 0.000 description 1
- 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 102100038002 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit STT3A Human genes 0.000 description 1
- 101710133440 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit STT3A Proteins 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101710136552 Fatty acid-binding protein, heart Proteins 0.000 description 1
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 description 1
- 101710188974 Fatty acid-binding protein, liver Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018378 Glomerulonephritis rapidly progressive Diseases 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 101710195403 Glutathione S-transferase P Proteins 0.000 description 1
- 102100030943 Glutathione S-transferase P Human genes 0.000 description 1
- 101710112368 Glutathione S-transferase P 1 Proteins 0.000 description 1
- 101710112365 Glutathione S-transferase P 2 Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 108010073791 Glycine amidinotransferase Proteins 0.000 description 1
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102000007343 Hepatitis A Virus Cellular Receptor 1 Human genes 0.000 description 1
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101001027663 Homo sapiens Fatty acid-binding protein, heart Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000999377 Homo sapiens Interferon-related developmental regulator 1 Proteins 0.000 description 1
- 101000881168 Homo sapiens SPARC Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 1
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 1
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
- 102000004883 Insulin-like growth factor-binding protein 6 Human genes 0.000 description 1
- 108090001014 Insulin-like growth factor-binding protein 6 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100036527 Interferon-related developmental regulator 1 Human genes 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000049772 Interleukin-16 Human genes 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000037862 Ion Transporter Human genes 0.000 description 1
- 108091006671 Ion Transporter Proteins 0.000 description 1
- 108010013792 Isovaleryl-CoA Dehydrogenase Proteins 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 201000003129 Kidney Papillary Necrosis Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
- 208000009378 Low Cardiac Output Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100033468 Lysozyme C Human genes 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108050006600 Metalloproteinase inhibitor 3 Proteins 0.000 description 1
- 102100030335 Midkine Human genes 0.000 description 1
- 108010092801 Midkine Proteins 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101000605526 Mus musculus Kallikrein-1 Proteins 0.000 description 1
- 102000005717 Myeloma Proteins Human genes 0.000 description 1
- 108010045503 Myeloma Proteins Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000009065 Netrin-1 Human genes 0.000 description 1
- 108010074223 Netrin-1 Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 102100035591 POU domain, class 2, transcription factor 2 Human genes 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 101000621511 Potato virus M (strain German) RNA silencing suppressor Proteins 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100030122 Protein O-GlcNAcase Human genes 0.000 description 1
- 102000005569 Protein Phosphatase 1 Human genes 0.000 description 1
- 108010059000 Protein Phosphatase 1 Proteins 0.000 description 1
- 102100032421 Protein S100-A6 Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 101000999374 Rattus norvegicus Interferon-related developmental regulator 1 Proteins 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 206010038548 Renal vein thrombosis Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108010005260 S100 Calcium Binding Protein A6 Proteins 0.000 description 1
- 108091006735 SLC22A2 Proteins 0.000 description 1
- 108091006649 SLC9A3 Proteins 0.000 description 1
- 102100037599 SPARC Human genes 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 108010045517 Serum Amyloid P-Component Proteins 0.000 description 1
- 102100036202 Serum amyloid P-component Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 102100030375 Sodium/hydrogen exchanger 3 Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 102100033470 Tubulointerstitial nephritis antigen Human genes 0.000 description 1
- 101710185398 Tubulointerstitial nephritis antigen Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 208000004608 Ureteral Obstruction Diseases 0.000 description 1
- 206010046479 Urethral valves Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010058990 Venous occlusion Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 description 1
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 201000008244 anti-basement membrane glomerulonephritis Diseases 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000013398 bayesian method Methods 0.000 description 1
- 238000013531 bayesian neural network Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002665 bowman capsule Anatomy 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000007413 cholesterol embolism Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical class NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 201000005637 crescentic glomerulonephritis Diseases 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- NYPJDWWKZLNGGM-RPWUZVMVSA-N esfenvalerate Chemical compound C=1C([C@@H](C#N)OC(=O)[C@@H](C(C)C)C=2C=CC(Cl)=CC=2)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-RPWUZVMVSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000005086 glomerual capillary Anatomy 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 201000011200 hepatorenal syndrome Diseases 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 229940118526 interleukin-9 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000000193 iodinated contrast media Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000637 nephrotoxin Toxicity 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 208000009291 paraphimosis Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 206010034878 phimosis Diseases 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 108091000053 retinol binding Proteins 0.000 description 1
- 102000029752 retinol binding Human genes 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 201000001988 urethral stricture Diseases 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000011547 urine creatinine measurement Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
- 230000009723 vascular congestion Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15039509P | 2009-02-06 | 2009-02-06 | |
| US61/150,395 | 2009-02-06 | ||
| US16241509P | 2009-03-23 | 2009-03-23 | |
| US61/162,415 | 2009-03-23 | ||
| PCT/US2010/023297 WO2010091236A1 (en) | 2009-02-06 | 2010-02-05 | Methods and compositions for diagnosis and prognosis of renal injury and failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2010210540A1 AU2010210540A1 (en) | 2011-09-15 |
| AU2010210540B2 true AU2010210540B2 (en) | 2015-06-18 |
Family
ID=42542390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010210540A Ceased AU2010210540B2 (en) | 2009-02-06 | 2010-02-05 | Methods and compositions for diagnosis and prognosis of renal injury and failure |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120053072A1 (https=) |
| EP (1) | EP2394166B1 (https=) |
| JP (1) | JP2012517594A (https=) |
| CN (1) | CN102439441B (https=) |
| AU (1) | AU2010210540B2 (https=) |
| CA (1) | CA2751435A1 (https=) |
| NZ (2) | NZ601575A (https=) |
| WO (1) | WO2010091236A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ610356A (en) | 2008-08-28 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CA2735590A1 (en) | 2008-08-29 | 2010-03-04 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| NZ607703A (en) | 2008-10-21 | 2014-09-26 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN102264230B (zh) | 2008-11-10 | 2014-12-10 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| US9229010B2 (en) | 2009-02-06 | 2016-01-05 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CA2770393A1 (en) | 2009-08-07 | 2011-02-10 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2496942B1 (en) | 2009-11-07 | 2017-03-22 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| JP5763098B2 (ja) | 2009-12-20 | 2015-08-12 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| PT2666872T (pt) | 2010-02-05 | 2016-07-08 | Astute Medical Inc | Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal |
| EP3070474A3 (en) | 2010-02-26 | 2016-12-07 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| NZ605698A (en) | 2010-06-23 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| IN2012MN02812A (https=) | 2010-06-23 | 2015-05-22 | Astute Medical Inc | |
| CA2811438A1 (en) * | 2010-10-07 | 2012-04-12 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CA2824434A1 (en) * | 2011-01-08 | 2012-07-12 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2668499A4 (en) * | 2011-01-29 | 2015-05-27 | Astute Medical Inc | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE |
| TW201250248A (en) * | 2011-04-25 | 2012-12-16 | Kyowa Medex Co Ltd | Prognostication method of renal failure |
| ES2734494T3 (es) | 2011-12-08 | 2019-12-10 | Astute Medical Inc | Métodos y usos para el diagnóstico de una lesión renal y de una insuficiencia renal |
| IN2014MN01759A (https=) * | 2012-02-27 | 2015-07-03 | Astute Medical Inc | |
| TR201807542T4 (tr) | 2013-01-17 | 2018-06-21 | Astute Medical Inc | Böbrek hasarı ve böbrek yetmezliği teşhisi ve prognozuna yönelik metotlar ve bileşimler. |
| CN107709993A (zh) * | 2015-06-11 | 2018-02-16 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| CN109073620A (zh) * | 2016-02-22 | 2018-12-21 | 健康跨度Dx公司 | 用于预防或降低急性肾损伤的方法 |
| EP3465201A4 (en) | 2016-06-06 | 2020-08-26 | Astute Medical, Inc. | MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR |
| US11263275B1 (en) * | 2017-04-03 | 2022-03-01 | Massachusetts Mutual Life Insurance Company | Systems, devices, and methods for parallelized data structure processing |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0828159A1 (en) * | 1996-09-03 | 1998-03-11 | Bayer Corporation | Method for the detection of lysozyme |
| RU2180965C1 (ru) * | 2000-07-03 | 2002-03-27 | Габбасова Наталья Вадимовна | Способ дифференциальной диагностики заболеваний почек |
| US20030003588A1 (en) * | 2001-06-28 | 2003-01-02 | Comper Wayne D. | Method for kidney disease detection by protein profiling |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1429031A1 (ru) | 1986-06-20 | 1988-10-07 | Калининский Государственный Медицинский Институт | Способ дифференциальной диагностики гломерулонефрита и пиелонефрита |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| CA2072758A1 (en) | 1990-09-14 | 1992-03-15 | Kenneth Francis Buechler | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| CA2107894C (en) | 1991-04-10 | 2003-10-14 | Kenneth F. Buechler | Crosstalk inhibitors and their uses |
| EP0579767B1 (en) | 1991-04-11 | 2000-08-23 | Biosite Diagnostics Inc. | Novel conjugates and assays for simultaneous detection of multiple ligands |
| US6019944A (en) | 1992-05-21 | 2000-02-01 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membranes |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| AUPR005600A0 (en) * | 2000-09-12 | 2000-10-05 | University Of Sydney, The | Diagnostic assay |
| FI20010673A7 (fi) * | 2001-03-30 | 2002-10-01 | Metso Minerals Tampere Oy | Järjestelmä tiedon keräämiseksi |
| US7138229B2 (en) * | 2002-12-06 | 2006-11-21 | Renovar, Inc. | Systems and methods for characterizing kidney diseases |
| US7138230B2 (en) * | 2002-12-06 | 2006-11-21 | Renovar, Inc. | Systems and methods for characterizing kidney diseases |
| US20080090304A1 (en) * | 2006-10-13 | 2008-04-17 | Barasch Jonathan Matthew | Diagnosis and monitoring of chronic renal disease using ngal |
| US7662578B2 (en) * | 2006-04-21 | 2010-02-16 | Children's Hospital Medical Center | Method and kit for the early detection of impaired renal status |
| WO2008060607A2 (en) * | 2006-11-14 | 2008-05-22 | Biosite Incorporated | Methods and compositions for monitoring and risk prediction in cardiorenal syndrome |
| CN103399155A (zh) * | 2007-03-26 | 2013-11-20 | 诺瓦提斯公司 | 用于监测肾功能的预测性的肾安全性生物标志物和生物标志物标签 |
| JP5661457B2 (ja) * | 2007-06-06 | 2015-01-28 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． | 腎疾患の予測診断 |
-
2010
- 2010-02-05 EP EP10739155.9A patent/EP2394166B1/en not_active Not-in-force
- 2010-02-05 CN CN201080014932.1A patent/CN102439441B/zh not_active Expired - Fee Related
- 2010-02-05 JP JP2011549279A patent/JP2012517594A/ja active Pending
- 2010-02-05 CA CA2751435A patent/CA2751435A1/en not_active Abandoned
- 2010-02-05 WO PCT/US2010/023297 patent/WO2010091236A1/en not_active Ceased
- 2010-02-05 NZ NZ601575A patent/NZ601575A/en not_active IP Right Cessation
- 2010-02-05 US US13/148,031 patent/US20120053072A1/en not_active Abandoned
- 2010-02-05 AU AU2010210540A patent/AU2010210540B2/en not_active Ceased
- 2010-02-05 NZ NZ594771A patent/NZ594771A/xx not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0828159A1 (en) * | 1996-09-03 | 1998-03-11 | Bayer Corporation | Method for the detection of lysozyme |
| RU2180965C1 (ru) * | 2000-07-03 | 2002-03-27 | Габбасова Наталья Вадимовна | Способ дифференциальной диагностики заболеваний почек |
| US20030003588A1 (en) * | 2001-06-28 | 2003-01-02 | Comper Wayne D. | Method for kidney disease detection by protein profiling |
Non-Patent Citations (3)
| Title |
|---|
| EDELSTEIN, A. L., Advances in Chronic Kidney Disease, 2008, vol. 15, pages 222-234 * |
| SEVERINI, G., et al., Clinica Chinica Acta, 1987, vol. 163, pages 97-103 * |
| WILSON, A. T., et al., The journal of Pediatrics, 1950, vol. 36, pages 199-211 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20120053072A1 (en) | 2012-03-01 |
| WO2010091236A1 (en) | 2010-08-12 |
| HK1167455A1 (zh) | 2012-11-30 |
| CN102439441B (zh) | 2016-03-09 |
| CN102439441A (zh) | 2012-05-02 |
| EP2394166A1 (en) | 2011-12-14 |
| NZ601575A (en) | 2014-08-29 |
| EP2394166B1 (en) | 2016-07-13 |
| NZ594771A (en) | 2013-06-28 |
| WO2010091236A9 (en) | 2010-11-18 |
| EP2394166A4 (en) | 2012-09-26 |
| CA2751435A1 (en) | 2010-08-12 |
| AU2010210540A1 (en) | 2011-09-15 |
| JP2012517594A (ja) | 2012-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009313189B2 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| US9417250B2 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| AU2009285550B2 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| AU2009316387B2 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| AU2010210540B2 (en) | Methods and compositions for diagnosis and prognosis of renal injury and failure | |
| AU2009308375B2 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| US20120190051A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| AU2010210535B2 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| AU2010279249B2 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| AU2010210537B2 (en) | Diagnosis and prognosis of renal injury and renal failure | |
| AU2015200953A1 (en) | Methods and composition for diagnosis and prognosis of renal injury and renal failure | |
| AU2013226184A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| AU2015200266A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| AU2015202151A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| AU2015203434A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| AU2014212609A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |